Compare the duration of pain relief after giving injection bupivacaine or injection ropivacaine in patients after abdominal surgeries

A comparative study of injection 0.25% bupivacaine and injection 0.25% ropivacaine for their duration of post-operative analgesia in USG guided transversus abdominis plane block for open abdominal surgeries

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016137

Enrollment

100

Registered

2018-10-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K00-K95- Diseases of the digestive system Health Condition 2: N00-N99- Diseases of the genitourinary system Health Condition 3: C00-D49- Neoplasms Health Condition 4: O00-O9A- Pregnancy, childbirth and the puerperium

Interventions

Intervention1: bupivacaine 0.25%: 20 ml drug will be given through ultrasound guided TAP block after surgery Control Intervention1: ropivacaine 0.25%: 20 ml drug will be given through ultrasound guide

Eligibility

Inclusion criteria

Inclusion criteria: Patient of physical status 1&2 Patient willing to participate Patient undergoing open abdominal surgery

Exclusion criteria

Exclusion criteria: Patient refusal to participate Patient with known sensitivity to local anesthetics Patient with infection at injection site patient with clotting abnormalities

Design outcomes

Primary

Measure	Time frame
To compare the efficacy ofUSG guided TAP block with 0.25% bupivacaine and 0.25% ropivacaine for postoperative analgesia in open abdominal surgeriesTimepoint: 0,2,4,6,8,10,12,16,20,24 hours	—

Secondary

Measure	Time frame
To look for any significant adverse effect of these drugsTimepoint: 0,2,4,6,8,10,12,16,20,24 hours	—

Countries

India

Contacts

Public ContactDr Prof K H Raghwendra

Indira Gandhi Institute Of Medical Science Sheikhpura Patna

dr.khraghwendra@ymail.com9835092798

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026